Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 7/20 | 0.77 |
| ▸ | GSK3A | P49840 | 2/20 | 0.70 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.70 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.70 |
| ▸ | PNP | P00491 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 1/20 | 0.66 |
| ▸ | TGM2 | P21980 | 1/20 | 0.61 |
| ▸ | KRAS | P01116 | 7/20 | 0.60 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733243 | 0.94 | HINT1 (0.76) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL8450059 | 0.92 | HINT1 (0.73) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL6363921 | 0.91 | HINT1 (0.65) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL217117 | 0.90 | HINT1 (0.80) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL7151774 | 0.89 | HINT1 (0.63) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL7159486 | 0.89 | HINT1 (0.62) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL1138806 | 0.89 | HINT1 (0.71) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL5663210 | 0.88 | HINT1 (0.61) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295418 | 0.88 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP | |
| SCHEMBL9295421 | 0.88 | HINT1 (0.75) | HINT1GSK3ARPS6KA3MAPK14PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113956313-A | Purification method of N-isobutyrylguanosine | 马鞍山致研生物医药科技有限公司 | 2022-01-21 | — | — | CN | claimed |
| CN-113817002-A | Preparation method of N-isobutyrylguanosine | 马鞍山致研生物医药科技有限公司 | 2021-12-21 | — | — | CN | claimed |
| CN-1309732-C | Method for preparing 6-alkoxy-2',3'-double deoxidated guanosine | CHANGAO SCIENCE AND TECHNOLOGY (CN) | 2007-04-11 | — | — | CN | claimed |
| CN-1415622-A | Method for preparing 6-alkoxy-2',3'-double deoxidated guanosine | CHANGAO SCIENCE AND TECHNOLOGY (CN) | 2003-05-07 | — | — | CN | claimed |
| EP-0640091-A4 | SYNTHESIS OF NUCLEOTIDE MONOMERS. | RIBOZYME PHARM INC (US) | 1995-07-26 | — | — | EP | claimed |
| EP-0640091-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1995-03-01 | — | — | EP | claimed |
| WO-1994001445-A1 | BASE-PROTECTED NUCLEOTIDE ANALOGS WITH PROTECTED THIOL GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1994-01-20 | — | — | WO | claimed |
| WO-1993023413-A1 | SYNTHESIS OF NUCLEOTIDE MONOMERS | RIBOZYME PHARMACEUTICALS, INC. (US) | 1993-11-25 | — | — | WO | claimed |
| US-20260125413-A1 | UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | AM CHEMICALS LLC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4577539-A1 | UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | AM Chemicals Llc (US) | 2025-07-02 | — | — | EP | disclosed |
| CN-118852302-B | Preparation method of compound | 天津兴博润生物制药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118852302-A | Preparation method of compound | 天津兴博润生物制药有限公司 | 2024-10-29 | — | — | CN | disclosed |
| EP-4367237-A2 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| WO-2024081970-A2 | NOVEL ANTISENSE OLIGONUCLEOTIDES CONTAINING HYBRID MORPHOLINO AND DNA/RNA(MODIFIED) WITH PHOSPHOROTHIOATE (PS) LINKER FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-0381335-A1 | Antiviral agent and novel nucleoside | TANABE SEIYAKU CO., LTD. (JP) | 1990-08-08 | — | — | EP | disclosed |
| EP-0320103-A2 | Compounds for DNA deletion and oligomers used therefor as well as a method for use thereof | AJINOMOTO CO., INC. (JP) | 1989-06-14 | — | — | EP | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| EP-0261552-A1 | Genetic engineering method to produce salmon calcitonin, and means to carry out this method | HOECHST AKTIENGESELLSCHAFT (DE) | 1988-03-30 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125413-A1 | UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS | SSU72, NSUN2, POLR2H | HINT1 3192/4885GSK3A 4268/4885RPS6KA3 1932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.